Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.